Open AccessFilgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial
Author(s) -
Walter P. Maksymowych,
Mikkel Østergaard,
Robert Landewé,
William T. Barchuk,
Ke Liu,
L. Gilles,
Thijs Hendrikx,
R. Besuyen,
Xenofon Baraliakos
Publication year - 2021
Publication title -
rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.957
H-Index - 173
eISSN - 1462-0332
pISSN - 1462-0324
DOI - 10.1093/rheumatology/keab758
Subject(s) - medicine , ankylosing spondylitis , placebo , spondylitis , basfi , basdai , surgery , nuclear medicine , pathology , arthritis , alternative medicine , psoriatic arthritis
To assess the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active AS in the TORTUGA trial.